FY12/22
Financial Results Briefing Materials
February 13, 2022
D. Western Therapeutics Institute, Inc.
Stock Code: 4576
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved.
Table of Contents
- FY12/22 Financial Results
- Progress of Business in FY12/22
- FY12/23 Forecast
(Reference) Business Overview
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved. | 2 |
1. FY12/22 Financial Results
January 1-December 31, 2022
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved. | 3 |
Consolidated Statement of Income (YoY comparison)
726 | (JPYmn) | ||||||||||||
565 | |||||||||||||
414 | 448 | 469 | |||||||||||
316 | 249 | 256 | |||||||||||
20 | 27 | Loss attributable to | |||||||||||
Net sales | Cost of sales SG&A expenses(R&D expenses) | (Other) | Operating loss | Ordinary loss | owners of parent | ||||||||
(148) | |||||||||||||
(171) | (159) | ||||||||||||
FY12/21 | FY12/22 | (305) | (295) | (429) | |||||||||
Net sales
- Royalty revenue grew 30.1% YoY, because sales of DW-1002 increased 22.2% YoY in Europe, US, and Canada, with a favorable forex impact (+7.8% YoY).
- Net sales rose 8.1% YoY, underpinned by milestone revenue accompanying the start of domestic Phase I study of DW- 1001 and receiving payment on transfer of exclusive enforcement rights to subsidiary JIT's corneal endothelium therapeutic agents.
R&D expenses
- R&D expenses rose 48.5% YoYdue to increased spending on development of H-1337 (Phase IIb study in the US) and DWR-2206.
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved. | 4 |
Consolidated Statement of Income (vs. full-year forecast)
(JPYmn)
FY12/21 | FY12/22 | ||||||||
FY results | FY results | YoY change | FY forecast | FY forecast | % of initial | Primary factors | |||
(out Feb.10) | (out Nov.18) | forecast | |||||||
• Royalty revenue from DW-1002 far exceeded initial | |||||||||
Net sales | 414 | 448 | 33 | 370 | 440 | 121.1％ | forecast | ||
• Received one-time payment for transfer of exclusive | |||||||||
enforcement rights to subsidiary JIT's corneal | |||||||||
endothelium therapeutic agents. | |||||||||
SG&A expenses | 565 | 726 | 160 | ||||||
R&D expenses | 316 | 469 | 153 | 790 | Undisclosed | 59.4％ | • Reduced due to the development cost of H-1337 | ||
being lower than expected | |||||||||
Other SG&A | 249 | 256 | 7 | ||||||
expenses | |||||||||
Operating loss | (171) | (305) | (134) | (690) | (400) | － |
Ordinary loss | (159) | (295) | (136) | (700) | (390) | － |
Loss attributable | (148) | (429) | (280) | (670) | (380) | － |
to owners of | ||||||
parent |
Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved. | 5 |